These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 31694342)
1. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342 [TBL] [Abstract][Full Text] [Related]
2. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M; J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633 [TBL] [Abstract][Full Text] [Related]
3. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500 [TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495 [TBL] [Abstract][Full Text] [Related]
6. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051 [TBL] [Abstract][Full Text] [Related]
7. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. Masliah-Planchon J; Pasmant E; Luscan A; Laurendeau I; Ortonne N; Hivelin M; Varin J; Valeyrie-Allanore L; Dumaine V; Lantieri L; Leroy K; Parfait B; Wolkenstein P; Vidaud M; Vidaud D; Bièche I BMC Genomics; 2013 Jul; 14():473. PubMed ID: 23848554 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917 [TBL] [Abstract][Full Text] [Related]
10. The role of miRNAs and lncRNAs in neurofibromatosis type 1. Khosravi T; Oladnabi M J Cell Biochem; 2023 Jan; 124(1):17-30. PubMed ID: 36345594 [TBL] [Abstract][Full Text] [Related]
11. An emerging role for microRNAs in NF1 tumorigenesis. Sedani A; Cooper DN; Upadhyaya M Hum Genomics; 2012 Nov; 6(1):23. PubMed ID: 23158014 [TBL] [Abstract][Full Text] [Related]
12. Peripheral nerve tumors in neurofibromatosis 1: An overview on management and indications for surgical treatment in our experience. Garozzo D Neurol India; 2019; 67(Supplement):S38-S44. PubMed ID: 30688231 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas. Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150 [TBL] [Abstract][Full Text] [Related]
14. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697 [TBL] [Abstract][Full Text] [Related]
15. Neurological malignancies in neurofibromatosis type 1. Eoli M; Saletti V; Finocchiaro G Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563 [TBL] [Abstract][Full Text] [Related]
16. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. Ars E; Kruyer H; Morell M; Pros E; Serra E; Ravella A; Estivill X; Lázaro C J Med Genet; 2003 Jun; 40(6):e82. PubMed ID: 12807981 [No Abstract] [Full Text] [Related]
17. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698 [TBL] [Abstract][Full Text] [Related]
20. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]